News and Trends 6 Jul 2022 New discovery center to house scientists opens in India A discovery services center spanning 100,000 sq ft has been set up in Pune, India, to house a talent of chemists, biologists and formulation scientists. TCG Lifesciences Pvt. Limited (TCGLS), in charge of facilitating the center, is a global contract research and contract development and manufacturing company delivering research and development services in the pharmaceutical […] July 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Poxel publishes ALD studies Two preclinical articles have been published in different journals for treatments being developed by French biopharmaceutical company, Poxel. Poxel develops treatments for chronic, serious diseases with metabolic pathophysiology including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The articles have been about genetic disease X-Linked Adrenoleukodystrophy (ALD) and molecules PXL065 and PXL770. These molecules have separate […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Destiny Pharma announces start of new oral mucositis research program Oral mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2 million cancer patients every year. Destiny Pharma plc, a clinical-stage biotech company focused on the development of novel medicines that can prevent life-threatening infections, has started a new research program on the condition. The research study will be […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Sanofi Global Health launches 30 nonprofit medicines in low-income countries Medicines specifically for the world’s most impoverished countries and at-risk populations have been produced and launched by Sanofi. The announcement was made at a global health stakeholders meeting in Paris. The standard of care medicines have formed the Impact brand which includes insulin, glibenclamide and oxaliplatin among others. A secure distribution of 30 Sanofi medicines […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential gene therapy products for a specific target disease related to the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology. MTPC and EditForce aim to create potential novel pharmaceuticals for the […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […] July 5, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Evotec completes acquisition of Rigenerand An Italian-based cell therapy business has just been bought by Evotec SE, a German therapeutics company. Evotec just announced the strategic transaction to buy Rigenerand Srl, with the deal, signed in May 2022, now completed. Based out of Medolla, Italy, the cell technology company working in the field of cGMP manufacturing of cell therapies will […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Mogrify and Astellas to address sensorineural hearing loss Biopharma company Mogrify Limited, and Japanese regenerative medicine firm Astellas Pharma Inc., have announced a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Utilizing Mogrify’s direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair […] July 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Positive news from trial for drug to treat major depressive disorder A company working on treatments for people with mental health issues has had positive feedback from the development program of an anti-depressant targeting major depressive disorder (MDD). ANeuroTech has just announced that after a successful pre-Investigational New Drug Application (IND) meeting, the US Food and Drug Administration (FDA) has given positive feedback on its […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 AstraZeneca adds to its treatments for blood cancer with $100M deal AstraZeneca announced today (July 5) it has agreed to buy a company working on a cancer cure. The company will hand over $100 million for TeneoTwo, Inc. in an upfront payment that will include its phase 1 clinical-stage CD19/CD3 T-cell engager, TNB-486, that is being evaluated in relapsed and refractory B-cell non-Hodgkin lymphoma. With the […] July 5, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 5 Jul 2022 The biggest US biotech investments in June 2022 In addition to recent Independence Day festivities, the U.S. biotech space has other reasons to celebrate. The asthma drug developer Upstream Bio topped the ranks for the U.S.’ biggest early-stage biotech investment in June 2022, but manufacturing heavyweight National Resilience, Inc. bagged the private funding top spot with a huge Series D round. In June […] July 5, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Brii Bio takes hepatitis B treatment option Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in […] July 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email